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Background: Progression of ﬁbrosis and ensuing complications determine the postoperative course of 
patients operated on for biliary atresia. We evaluated predictors of the progression of ﬁbrosis in the 
native liver after operative treatment. 
Methods: Among patients whose bilirubin decreased to < 34 μmol/L after portoenterostomy ( n = 41), pre- 
dictors of follow-up cirrhosis and the progression of ﬁbrosis were analyzed with logistic regression and 
survival of their native liver was evaluated with the Kaplan-Meier method. Areas under receiving operat- 
ing characteristic were used to deﬁne optimal cutoffs. 
Results: After median follow-up of 5.2 years (interquartile range 1.6–10.2) after portoenterostomy, liver 
biopsies showed cirrhosis in 53% of patients, and the Metavir stage remained stable or decreased in 38%. 
The development of cirrhosis was predicted by total or conjugated bilirubin ≥170/120 μmol/L at the time 
of portoenterostomy ( P ≤ .009); normalization of bilirubin within 1.9 months ( P = .002); total or con- 
jugated bilirubin ≥ 12.5/7.5 μmol/L ( P = .002) and aspartate aminotransferase-to-platelet ratio ≥ 0.55 at 
3 months postoperatively ( P = .001); and total or conjugated bilirubin ≥ 7.5/2.5 μmol/L ( P ≤ .001), as- 
partate aminotransferase-to-platelet ratio ≥ 0.63 ( P = .004), and gamma glutamyl transferase ≥ 266 U/L 
( P = .007) at 6 months postoperatively. In multiple regression analysis, conjugated bilirubin ≥ 2.5 μmol/L 
at 6 months increased the risk of cirrhosis 35-fold ( P = .020), and other predictors were not predictive. 
Total or conjugated bilirubin < 12.5/7.5 μmol/L ( P ≤ .014), aspartate aminotransferase-to-platelet ratio < 
0.55 at 3 months ( P = .006), and total or conjugated bilirubin < 7.5/2.5 μmol/L at 6 months postopera- 
tively ( P ≤ .014) were the strongest predictors of a stable, nonprogressive ﬁbrosis. Decreases in total or 
conjugated bilirubin to < 12.5/7.5 μmol/L by 3 months and to < 7.5/2.5 μmol/L by 6 months improved 
survival of the native liver (log-rank P ≤ .025). Age at follow-up or at portoenterostomy, anatomic type of 
biliary atresia, use of postoperative steroids, and episodes of cholangitis were unrelated to the progression 
of ﬁbrosis or the development of cirrhosis ( P = not signiﬁcant). 
Conclusion: Among patients whose serum bilirubin normalizes after portoenterostomy, its rapid decrease 
to very low levels prolongs the survival of their native liver by delaying the progression of ﬁbrosis. 
© 2018 Elsevier Inc. All rights reserved. 
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Biliary atresia (BA) is a rare cholangiopathy of the newborn,
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native liver in patients with biliary atresia by deferring liver ﬁbrogeneshich results in cholestasis and rapidly progressive biliary cirrho-
is. After portoenterostomy (PEostomy) aiming to restore bile ﬂow,
ore than half of patients achieve clearance of jaundice (COJ),
ffectively postponing the need for liver transplantation (LT). 1–4 
espite normalization of serum bilirubin by successful PEostomy,
owever, liver injury progresses chronically, resulting almost in-
ariably in cirrhosis 5–8 and warranting LT in 75%–80% of patients
y adult age. 6,8 , 9 
As in other chronic liver diseases, the postoperative course of
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r  ensuing complications. 10–12 Patients who fail to clear their jaun-
dice after PEostomy develop cirrhosis and end-stage liver disease
rapidly. The disease course is far more variable after a success-
ful PEostomy, which enables prolonged survival with the native
liver. As long-term ﬁbrosis of the native liver has rarely been stud-
ied, no reliable means exist to predict in which patients liver
ﬁbrosis progresses, remains stable, or even resolves after clear-
ance of jaundice (COJ), although noninvasive methods may be use-
ful in estimating the current stage of ﬁbrosis in the liver. 12,13 
Although overall survival of the native liver after PEostomy de-
pends strongly on the postoperative decrease in serum bilirubin to
< 34 μmol/L (2 mg/dL), 14–16 it remains unclear how different
patient- and treatment-related factors predict progression of liver
ﬁbrosis among patients who reach normal serum bilirubin levels
after PEostomy. Identifying early predictors of progressive liver ﬁ-
brosis would facilitate targeting intensive postoperative monitoring
to children at the greatest risk for cirrhosis and its complications.
To increase our understanding of the chronic liver disease devel-
oping after successful PEostomy and to improve patient follow-
up, we analyzed predictors for progression of liver ﬁbrosis and
studied their effect on survival of the native liver among patients
who cleared their jaundice after PEostomy and underwent protocol
surveillance liver biopsies. 
Materials and Methods 
Patients and study design 
Helsinki University Children’s Hospital, Finland, is a tertiary re-
ferral center for pediatric hepatobiliary surgery and is respon-
sible for treatment of BA in Finland. 1 All BA patients managed
in Helsinki during 1990–2016 who cleared their jaundice after
PEostomy ( n = 42, 65% of all BA patients) and had undergone a
follow-up liver biopsy were included in the present study. The
diagnosis of BA was conﬁrmed by intraoperative cholangiography
and a histopathologic assessment of the biliary remnant. For this
study, COJ was deﬁned as plasma total bilirubin < 34 μmol/L
(2 mg/dL) 15–17 while living with the native liver after PEostomy.
Follow-up ended at the time of last follow-up liver biopsy, when
survival status of the native liver was recorded. The study protocol
was approved by the hospital ethical committee. 
The patient records and our prospective BA database were re-
viewed for relevant medical and surgical history. Use of postop-
erative steroids, ursodeoxycholic acid, and prophylactic antibiotics
were recorded. 1,18 , 19 The cumulative dose of steroids received post-
operatively was calculated and expressed as equivalent dose of
prednisolone (mg/kg). 20 Postoperative febrile episodes without any
other identiﬁed cause treated with antibiotics were assumed to
be cholangitis and deﬁned as such, and their occurrence during
follow-up was registered. 
Liver biopsies 
Patients underwent liver biopsies at PEostomy and during
follow-up at the age of 1, 5, 10, and 15 years, according to
our postoperative follow-up protocol. 1,10 Liver biopsies obtained at
PEostomy and at last follow-up were included. Follow-up biop-
sies were core needle biopsies performed either percutaneously
under ultrasonographic guidance under general anesthesia during
endoscopic variceal surveillance 10 or intraoperatively at time of LT.
Biopsies containing at least 10 portal areas were considered repre-
sentative and included in the analyses. The specimens were graded
for degrees of ﬁbrosis by using hematoxylin and eosin staining
and Herovici staining. 1 We applied the Metavir ﬁbrosis staging,
where stage 1 corresponds to ﬁbrous portal expansion without for-
mation of septa, stage 2 indicates portal ﬁbrosis with occasionalPlease cite this article as: M. Hukkinen, A. Kerola and J. Lohi et al., Ve
native liver in patients with biliary atresia by deferring liver ﬁbrogenesortal-to-portal septa, stage 3 portal includes ﬁbrosis with numer-
us septa, and stage 4 represents cirrhosis. 21 The specimens were
ereviewed by two experienced pediatric pathologists blinded to
linical data until consensus was reached. Progression of liver ﬁ-
rosis over follow-up time was deﬁned as the difference between
he Metavir stages at the time of PEostomy and at follow-up, and
hanges ≤ 0 were considered as stable, nonprogressive ﬁbrosis. Pa-
ients with cirrhosis (Metavir stage 4) at PEostomy ( n = 4) or no
iver biopsy taken at PEostomy ( n = 5) were excluded from the
nalyses of ﬁbrosis progression. Blood count, liver biochemistry,
nd coagulation parameters were checked before liver biopsy, and
atients were followed overnight in the hospital afterward. No
omplications of the liver biopsies were registered. 
iver biochemistry and portal hypertension 
Liver function test results, including total and conjugated biliru-
in, aspartate aminotransferase (AST), platelets, and gamma glu-
amyl transferase (GT) were recorded at PEostomy and at 3 and
 months after PEostomy at the time of follow-up visits. Only mea-
urements performed by our hospital laboratory were included. As-
artate aminotransferase-to-platelet ratio (APRI) was calculated ac-
ording to the following formula: [(AST / upper normal limit of
ormal) ×100] / platelet count (10 9 /L). 22 Portal hypertension was
eﬁned as the occurrence of esophageal or gastric varices at any
ime during follow-up or thrombocytopenia ( < 150 ×10 9 /L) in as-
ociation with splenomegaly on ultrasonography. 17 
tatistical methods 
Continuous data are expressed as median values with interquar-
ile ranges and categorical data as frequencies. The Mann-Whitney
 test was used to compare continuous variables, and the Fisher
xact test compared frequencies between subgroups. Variables
howing statistically signiﬁcant differences between cirrhotic pa-
ients and other patients were further analyzed in the prediction
f follow-up cirrhosis. The receiving operating characteristic (ROC)
urves and their areas under ROC (AUROC) curves with 95% con-
dence intervals (CI) were calculated, and the best cutoff values
ere deﬁned according to the highest sum of sensitivity and speci-
city. Optimal cutoff values of these variables were then used in
ogistic regression models with follow-up cirrhosis and progression
f ﬁbrosis as primary outcomes. Statistically signiﬁcant predictors
rom simple regression models were included in multiple regres-
ion; however, if correlation between covariates exceeded 0.65, the
ariable with a lesser odds ratio (OR) was omitted from the multi-
le regression. Finally, cumulative survival rates of the native liver
ere analyzed with the Kaplan-Meier method by calculating uni-
ariate predictors of survival with the log-rank test. The level of
igniﬁcance was set at P < .05, and all analyses were performed
ith SPSS version 24 (IBM Corp, Armonk, NY). 
thics 
The study protocol was approved by the Helsinki University
hildren’s Hospital, Finland, ethical committee (protocol number
45/03/1372008). Institutional approval was renewed on July 21,
017 (§68 HUS/149/2017). 
esults 
atient characteristics and their relation to liver ﬁbrosis 
Of the 42 patients clearing their jaundice after PEostomy, 1 was
xcluded because no follow-up liver biopsy was available. Of the
emaining 41 patients, half ( n = 22) were women, 85% had typery low bilirubin after portoenterostomy improves survival of the 
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Table 1 
Characteristics of patients having cleared their jaundice according to the presence of cirrhosis at last follow-up ∗
Variable All patients ( n = 41) Patients without cirrhosis at 
follow-up ( n = 19) 
Patients with cirrhosis at follow-up 
( n = 22) 
P value 
Age at follow-up (years) 5.2 (1.6–10.2) 4.5 (1.4–10.3) 5.4 (2.2–10.1) .774 
Age at PEostomy (days) 58 (30–79) 54 (25–75) 61 (37–85) .488 
Type of biliary atresia, n (%) 
1 or 2 6 (15) 3 (16) 3 (14) 
3 35 (85) 16 (84) 19 (86) 1.0 0 0 
Associated malformations, n (%) 15 (37) 9 (47) 6 (27) .211 
Polysplenia, n (%) 7 (17) 3 (16) 4 (18) 1.0 0 0 
Total bilirubin at PEostomy (μmol/L), 
[mg/dL] † 
149 (110–205) [8.7 (6.4–12)] 136 (103–168) [8.0 (6.0–9.8)] 177 (139–215) [10.4 (8.1–12.6)] .037 
Conjugated bilirubin at PEostomy 
(μmol/L), [mg/dL] ‡ 
101 (83–154) [5.9 (4.9–9.0)] 98 (78–117) [5.7 (4.6–6.8)] 125 (84–175) [7.3 (4.9–10.2)] .059 
APRI at PEostomy § 0.90 (0.48–1.24) 0.78 (0.52–0.92) 1.05 (0.51–1.48) .232 
Metavir ﬁbrosis stage at PEostomy, ¶ n (%) 
1 2 (5.6) 0 (0) 2 (10) .987 
2 19 (53) 9 (56) 10 (50) 
3 11 (31) 7 (44) 4 (20) 
4 4 (11) 0 (0) 4 (20) 
Metavir ﬁbrosis stage at follow-up, n (%) 
1 3 (7.3) 3 (16) — < .001 
2 9 (22) 9 (47) —
3 7 (17) 7 (37) —
4 22 (53.7) — 22 (100) 
Steroids administered after PEostomy, n 
(%) 
34 (83) 16 (84) 18 (82) 1.0 0 0 
Cumulative prednisolone dose after 
PEostomy (mg/kg) 
48.1 (23.8–71.4) 46.8 (21.4–68.3) 49.1 (37.7–66.4) .751 
Time to clearance of jaundice (months) 1.97 (0.69–3.22) 0.93 (0.57–2.33) 2.69 (1.77–3.47) .011 
Total bilirubin at 3 months (μmol/L), 
[mg/dL] 
11 (6.0–20) [0.64 (0.35–1.2)] 6.0 (3.0–12) [0.35 (0.18–0.70)] 18 (10–27) [1.1 (0.58–1.6)] .001 
Conjugated bilirubin at 3 months 
(μmol/L), [mg/dL] 
5.5 (2.0–13) [0.32 (0.12–0.76)] 2.5 (2.0–5.5) [0.15 (0.12–0.32)] 12 (4.5–23) [0.70 (0.26–1.4)] < .001 
APRI at 3 months † 0.57 (0.34–0.96) 0.34 (0.21–0.50) 0.79 (0.57–1.14) .004 
GT at 3 months (U/L) ‡ 319 (227–565) 267 (140–49) 349 (265–633) .126 
Total bilirubin at 6 months (μmol/L), 
[mg/dL] 
8.0 (4.0–24) [0.47 (0.23–1.4)] 4.0 (3.0–7.5) [0.23 (0.18–0.44)] 14 (8.0–28) [0.82 (0.47–1.6)] < .001 
Conjugated bilirubin at 6 months 
(μmol/L), [mg/dL] 
3.0 (2.0–11) [0.18 (0.12–0.64)] 2.0 (-) [0.12 (-)] 8.0 (3.0–22) [0.47 (0.18–1.3)] < .001 
APRI at 6 months § 0.77 (0.40–1.40) 0.40 (0.26–1.11) 0.99 (0.65–1.45) .037 
GT at 6 months (U/L) † 232 (114–370) 153 (101–232) 300 (209–461) .005 
Cholangitis episodes/year 0.31 (0.00–1.29) 0.31 (0.04–0.77) 0.28 (0.00–2.26) .731 
Cholangitis within last year, n (%) 15 (37) 5 (26) 10 (45) .333 
Total number of cholangitis episodes, n (%) 
0 11 (27) 5 (26) 6 (27) 
1–2 12 (29) 8 (42) 4 (18) 
Three or more 18 (44) 6 (32) 12 (55) .214 
Listed for transplantation, n (%) 10 (24) 0 (0) 10 (45) .001 
∗ Continuous data are reported as median with interquartile range. 
† Results missing for 2 patients. 
‡ Results missing for 3 patients. 
§ Results missing for 4 patients. 
¶ Histology at portoenterostomy (PEostomy) missing for 5 patients. APRI , aspartate aminotransferase to platelet ratio. 
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i   BA, and the majority presented with Metavir ﬁbrosis stage 2
r 3 at time of PEostomy ( Table 1 ). All patients had received ur-
odeoxycholic acid and prophylactic antibiotics after PEostomy, and
teroids had been administered in 83% (34/41). 
At last follow-up at median age of 5.2 (1.6–10.2) years, all pa-
ients were alive, and liver biopsy showed cirrhosis in 22 (53%).
he stage of ﬁbrosis had remained unchanged ( n = 5) or decreased
 n = 7) during follow-up in 38% of patients ( Table 2 ). Follow-up cir-
hosis and progression of ﬁbrosis were unrelated with follow-up
ge, PEostomy age, anatomic type of BA, postoperative administra-
ion of steroids, the cumulative steroid dose, episodes of cholangi-
is, or associated anomalies ( Tables 1 and 2 ), and the Metavir stage
t PEostomy was less among patients whose ﬁbrosis progressed
uring follow-up ( Table 2 ). Altogether 23 patients (56%) developed
ortal hypertension during follow-up and presented with cirrho-
is (18/23 vs 4/18, P = .001) and progressive ﬁbrosis (14/16 vs 6/16,
 = .009) more frequently than others. Patient age showed no cor-Please cite this article as: M. Hukkinen, A. Kerola and J. Lohi et al., Ve
native liver in patients with biliary atresia by deferring liver ﬁbrogeneselation with follow-up stage of ﬁbrosis stage or progression of ﬁ-
rosis ( P = not signiﬁcant for both; Supplementary Fig). 
rediction of follow-up cirrhosis 
Patients who presented with cirrhosis at follow-up had greater
reoperative serum bilirubin levels, greater levels of total biliru-
in, conjugated bilirubin, and APRI at 3 and 6 months after
Eostomy, and greater levels of GT at 6 months after PEostomy
ompared with others ( Table 1 ). They had also cleared their jaun-
ice markedly slower after PEostomy than patients without cir-
hosis ( Table 1 ). The variables showing statistically signiﬁcant dif-
erences between cirrhotic and noncirrhotic patients were further
valuated for their value in the prediction of cirrhosis by using AU-
OC analyses ( Table 3 ). By applying the deﬁned cutoffs in logistic
egression models, the risk for follow-up cirrhosis was increased
f total or conjugated bilirubin exceeded 170/120 μmol/L (10/7.0ry low bilirubin after portoenterostomy improves survival of the 
is, Surgery, https://doi.org/10.1016/j.surg.2018.10.032 
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Table 2 
Characteristics of patients having cleared their jaundice according to the progression of the Metavir stage ∗
Variable Patients with unprogressive ﬁbrosis ( n = 12) Patients with progressive ﬁbrosis ( n = 20) P value 
Age at follow-up (years) 4.4 (1.3–8.1) 4.3 (1.6–8.0) .924 
Age at PEostomy (days) 60 (25–77) 55 (34–73) .744 
Type of biliary atresia, n (%) 
1 or 2 2 (17) 2 (10) .620 
3 10 (83) 18 (90) 
Associated malformations, n (%) 6 (50) 6 (30) .288 
Polysplenia, n (%) 1 (8.3) 3 (15) 1.0 0 0 
Total bilirubin at PEostomy (μmol/L), [mg/dL] 132 (102–168) [7.7 (6.0–9.8)] 176 (111–211) [10 (6.5–12)] .107 
Conjugated bilirubin at PEostomy (μmol/L), [mg/dL] 100 (78–117) [5.9 (4.6–6.8)] 98 (83–166) [5.7 (4.9–9.7)] .477 
APRI at PEostomy † 0.78 (0.47–0.90) 0.84 (0.46–1.22) .641 
Metavir ﬁbrosis stage at PEostomy, n (%) 
1 0 (0) 2 (10) .048 
2 5 (42) 14 (70) 
3 7 (45) 4 (20) 
4 — —
Metavir ﬁbrosis stage at follow-up, n (%) 
1 2 (17) 0 < .001 
2 7 (58) 0 
3 3 (25) 4 (20) 
4 0 (0) 16 (80) 
Steroids administered after PEostomy, n (%) 10 (83) 18 (90) 1.0 0 0 
Cumulative prednisolone dose (mg/kg) after PEostomy 45.9 (21.4–60.4) 51.5 (43.6–73.8) .216 
Time to clearance of jaundice (months) 0.65 (0.50–1.93) 2.69 (1.63–3.47) .009 
Total bilirubin at 3 months (μmol/L), [mg/dL] 5.5 (3.0–9.0) [0.32 (0.18–0.53)] 18 (9.0–28) [1.1 (0.5–1.6)] .001 
Conjugated bilirubin at 3 months (μmol/L), [mg/dL] 2.0 (2.0–4.0) [0.12 (0.12–0.23)] 12 (3.5–22) [0.7 (0.2–1.3)] .004 
APRI at 3 months ‡ 0.34 (0.25–0.43) 0.69 (0.47–1.13) .003 
GT at 3 months (U/L) 267 (174–326) 347 (190–759) .239 
Total bilirubin at 6 months (μmol/L), [mg/dL] 3.5 (3.0–7.0) [0.20 (0.18–0.41)] 14 (6.0–27) [0.8 (0.35–1.6)] .011 
Conjugated bilirubin at 6 months (μmol/L), [mg/dL] 2.0 (-) [0.12 (-)] 8.0 (2.0–22) [0.47 (0.12–1.3)] .021 
APRI at 6 months § 0.40 (0.18–0.74) 0.99 (0.65–1.50) .016 
GT at 6 months (U/L) † 151 (113–227) 290 (108–412) .061 
Cholangitis episodes/year 0.39 (0.00–1.66) 0.33 (0.00–0.79) .716 
Cholangitis within last year, n (%) 4 (33) 7 (35) 1.0 0 0 
Total number of cholangitis episodes, n (%) 
0 4 (33) 6 (30) .535 
1–2 5 (42) 5 (25) 
3 or more 3 (25) 9 (45) 
Listed for transplantation, n (%) 0 (0) 7 (35) .029 
∗ Continuous data are reported as median with interquartile range. Unprogressive ﬁbrosis is deﬁned as the difference between Metavir stage at follow-up and 
at portoenterostomy (PEostomy) ≤ 0. Patients with cirrhosis at PEostomy ( n = 4) were excluded from the analysis. 
† Results missing for 2 patients. 
‡ Results missing for 1 patient. 
§ Results missing for 3 patients. APRI ; aspartate aminotransferase to platelet ratio; GT gamma glutamyl transferase. 
Table 3 
AUROC with 95% CI and best cutoff values for prediction of cirrhosis at follow-up ∗
Variable AUROC (95% CI) P value Optimal cutoff Sensitivity Speciﬁcity Reference 
Total bilirubin at PEostomy 0.70 (0.53–0.87) .037 171 μmol/L (10 mg/dL) 0.62 0.83 < 34 μmol/L ( < 2.0 mg/dL) 
Conjugated bilirubin at PEostomy 0.68 (0.50–0.86) .059 120 μmol/L (7.0 mg/dL) 0.55 0.90 < 5 μmol/L ( < 0.3 mg/dL) 
Time to COJ (months) 0.73 (0.57–0.89) .011 1.9 months 0.73 0.74 —
Total bilirubin at 3 months 0.82 (0.68–0.95) .001 12.5 μmol/L (0.73 mg/dL) 0.64 0.90 < 34 μmol/L ( < 2.0 mg/dL) 
Conjugated bilirubin at 3 months 0.83 (0.70–0.96) < .001 7.5 μmol/L (0.44 mg/dL) 0.70 0.90 < 5 μmol/L ( < 0.3 mg/dL) 
APRI at 3 months 0.77 (0.60–0.94) .004 0.55 0.77 0.82 —
Total bilirubin at 6 months 0.85 (0.73–0.97) < .001 7.5 μmol/L (0.44 mg/dL) 0.77 0.77 < 34 μmol/L ( < 2.0 mg/dL) 
Conjugated bilirubin at 6 months 0.84 (0.72–0.97) < .001 2.5 μmol/L (0.15 mg/dL) 0.81 0.77 < 5 μmol/L ( < 0.3 mg/dL) 
GT at 6 months 0.76 (0.61–0.91) 0.006 266 U/L 0.64 0.82 < 50 U/L 
APRI at 6 months 0.70 (0.51–0.89) .037 0.63 0.86 0.63 —
∗ The optimal cutoffs of statistically signiﬁcant predictors were used in regression analyses. AUROC , areas under receiving operating characteristic; CI , 
conﬁdence interval; AST, aspartate aminotransferase; APRI , AST to platelet ratio; GT , gamma glutamyl transferase. 
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p  mg/dL) at PE; 12.5/7.5 μmol/L (0.73/0.44 mg/dL) at 3 months af-
ter PE; or 7.5/2.5 μmol/L (0.44/0.15 mg/dL) at 6 months after PE
( Table 4 ). APRI values exceeding 0.55 at 3 months, and APRI ≥ 0.63
and GT ≥ 266 U/L at 6 months also increased the risk for cirrhosis
at follow-up ( Table 4 ). 
Statistically signiﬁcant variables from simple regression were
adjusted for in a multiple regression. In the ﬁnal model, only con-
jugated bilirubin at 6 months remained a signiﬁcant predictor,
with values ≥2.5 μmol/L ( ≥0.15 mg/dL) increasing the risk of cir-
rhosis 35-fold ( Table 4 ). Please cite this article as: M. Hukkinen, A. Kerola and J. Lohi et al., Ve
native liver in patients with biliary atresia by deferring liver ﬁbrogenesrediction of progressive ﬁbrosis 
Reﬂecting the ﬁndings in patients with established follow-up
irrhosis, patients with progressive ﬁbrosis had cleared their jaun-
ice signiﬁcantly later and had greater total and conjugated levels
f bilirubin as well as APRI at 3 and 6 months after PEostomy than
atients with stable, nonprogressive ﬁbrosis ( Table 2 ). The variables
howing signiﬁcant differences between the subgroups of patients
ith progression of ﬁbrosis were analyzed for the prediction of
rogressive ﬁbrosis, using the obtained cutoff values for predictionry low bilirubin after portoenterostomy improves survival of the 
is, Surgery, https://doi.org/10.1016/j.surg.2018.10.032 
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Table 4 
Predictors of follow-up cirrhosis assessed with simple logistic regression and multiple regression ∗
Variable Patients ( n ) Simple regression Multiple regression 
OR (95% CI) P value OR (95% CI) P value 
Total bilirubin at PEostomy † 
< 170 μmol/L ( < 10 mg/dL) 23 1.00 (Ref) .007 
≥ 170 μmol/L ( ≥ 10 mg/dL) 16 8.13 (1.78–37.17) 
Conjugated bilirubin at PEostomy ‡ 
< 120 μmol/L ( < 7.0 mg/dL) 25 1.00 (Ref) .009 1.00 (Ref) 
≥ 120 μmol/L ( ≥ 7.0 mg/dL) 13 9.78 (1.76–54.3) 20.1 (0.74–543) .075 
Time to clearance of jaundice 
< 1.9 months 22 1.00 (Ref) 
≥ 1.9 months 19 10.0 (2.35–42.5) .002 
Total bilirubin at 3 mo 
< 12.5 μmol/L ( < 0.73 mg/dL) 25 1.00 (Ref) 
≥ 12.5 μmol/L ( ≥ 0.73 mg/dL) 16 14.9 (2.71–81.7) .002 
Conjugated bilirubin at 3 mo 
< 7.5 μmol/L ( < 0.44 mg/dL) 23 1.00 (Ref) 
≥ 7.5 μmol/L ( ≥ 0.44 mg/dL) 18 11.4 (2.49–52.5) .002 
APRI at 3 mo † 
< 0.55 19 1.00 (Ref) 1.00 (Ref) 
≥ 0.55 20 15.9 (3.21–78.3) .001 10.8 (0.79–149) .075 
Total bilirubin at 6 mo 
< 7.5 μmol/L ( < 0.44 mg/dL) 20 1.00 (Ref) 
≥ 7.5 μmol/L ( ≥ 0.44 mg/dL) 21 12.8 (2.88–56.4) .001 
Conjugated bilirubin at 6 mo 
< 2.5 μmol/L ( < 0.15 mg/dL) V 1.00 (Ref) 1.00 (Ref) 
≥ 2.5 μmol/L ( ≥ 0.15 mg/dL) 21 24.0 (4.65–124) < .001 35.1 (1.74–708) .020 
APRI at 6 mo §
< 0.63 13 1.00 (Ref) 
≥ 0.63 24 10.0 (2.05–48.9) .004 
GT at 6 mo † 
< 266 U/L 17 1.00 (Ref) 1.00 (Ref) 
≥ 266 U/L 22 8.17 (2.79–37.3) .007 1.52 (0.08–28.2) .778 
∗ Statistically signiﬁcant variables from simple regression were adjusted for in multiple regression. Liver function tests with higher odds ratios (OR) in simple 
regression were chosen if signiﬁcant both 3 and 6 months after portoenterostomy (PEostomy). Conjugated instead of total bilirubin at PEostomy was chosen for the 
model because of its greater OR in simple regression, and conjugated bilirubin at 6 months was chosen because of its greater OR compared with other postoperative 
bilirubin measurements. ORs are reported with 95% conﬁdence intervals (CI). 
† Results missing for 2 patients. 
‡ Results missing for 3 patients. 
§ Results missing for 4 patients. APRI , aspartate aminotransferase to platelet ratio; GT , gamma glutamyl transferase. 
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a  f cirrhosis. In simple regression, greater total and conjugated
ilirubin and APRI both at 3 and 6 months after PEostomy and in-
reased GT at 6 months after PEostomy increased the likelihood of
rogressive ﬁbrosis during follow-up. Patients with Metavir stage
 at PEostomy were more likely to have stable nonprogressive liver
brosis compared with stages 1–2 ( Table 5 ). In the multiple regres-
ion model, however, none of the variables remained a statistically
igniﬁcant predictor for progression of ﬁbrosis ( Table 5 ). 
urvival of the native liver 
In comparison with 41% of cirrhotic patients, no patient with
he lesser Metavir stages of ﬁbrosis had been listed for LT
 Table 1 ). Accordingly, 35% of patients with progressive ﬁbrosis
uring follow-up had been listed for LT compared with none of
he patients with stable, nonprogressive ﬁbrosis ( Table 2 ). Indica-
ions for LT included hepatopulmonary syndrome ( n = 2), recurrent
astrointestinal bleeding ( n = 4), repeated episodes of cholangitis
 n = 2), ascites ( n = 1), and poor quality of life related with end-
tage liver disease ( n = 1). 
Next, we assessed survival of the native liver according to
he variables predictive of cirrhosis using optimal cutoffs obtained
rom AUROC analyses. A signiﬁcantly improved survival of the
ative liver was observed among patients with total bilirubin <
2.5 μmol/L ( < 0.73 mg/dL) and conjugated bilirubin < 7.5 μmol/L
 < 0.44 mg/dL) at 3 months after PEostomy and among those
ith total bilirubin < 7.5 μmol/L ( < 0.44 mg/dL) and conjugated
ilirubin < 2.5 μmol/L ( < 0.15 mg/dL) at 6 months after PEostomy
 Fig. 1 ). Survival of the native liver did not differ in relation to to-Please cite this article as: M. Hukkinen, A. Kerola and J. Lohi et al., Ve
native liver in patients with biliary atresia by deferring liver ﬁbrogenesal or conjugated bilirubin at time of PEostomy, postoperative APRI
r GT values, stage of ﬁbrosis at PE, or clearance of jaundice time
 P = not signiﬁcant for all). 
iscussion 
To our best knowledge, this is the ﬁrst study assessing the pro-
ression of histologic liver ﬁbrosis in patients who reach normal
ilirubin levels after PEostomy. Our results demonstrate that, even
fter serum bilirubin has decreased into normal reference range,
ostoperative bilirubin is a powerful predictor of liver ﬁbrosis pro-
ression and thus survival of the native liver in patients with BA.
ilirubin levels close to the upper reference limit at 3 to 6 months
fter PEostomy were associated strongly with progressive ﬁbrosis,
ollow-up cirrhosis, and decreased survival of the native liver. Post-
perative APRI and GT showed weaker associations with follow-
p histopathology; nevertheless, serum bilirubin remained the only
ariable related with cirrhosis in multiple regression and the only
tudied variable predictive of survival of the native liver. These
ndings demonstrate that, even after achieving COJ, the risk of
rogressive liver disease varies according to postoperative bilirubin
evels and suggests that the intensiveness of patient monitoring af-
er successful PEostomy may be guided by measuring bilirubin lev-
ls already at 3 and 6 months postoperatively. 
As ﬁbrosis progresses in most patients after COJ, or remains sta-
le, or even resolves over time in others, our ﬁndings may have
athophysiologic implications. 1,10 In BA and other chronic cholan-
iopathies, newly formed reactive cholangiocytes in ductular re-
ctions are believed to promote progression of ﬁbrosis, becausery low bilirubin after portoenterostomy improves survival of the 
is, Surgery, https://doi.org/10.1016/j.surg.2018.10.032 
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Table 5 
Predictors of the progression of ﬁbrosis assessed with simple logistic regression and multiple regression ∗
Variable Patients ( n ) Simple regression Multiple regression 
OR (95% CI) P value OR (95% CI) P value 
Liver ﬁbrosis stage at PEostomy 
1–2 21 5.60 (1.15–27.4) 11.6 (0.65–205) .094 
3 11 1.00 (Ref) .033 1.00 (Ref) 
Time to clearance of jaundice after PEostomy 
< 1.9 months 17 1.00 (Ref) 
≥ 1.9 months 15 9.29 (1.57–54.8) .014 
Total bilirubin at 3 mo 
< 12.5 μmol/L ( < 0.73 mg/dL) 19 1.00 (Ref) 
≥ 12.5 μmol/L ( ≥ 0.73 mg/dL) 13 16.5 (1.18–155) .014 
Conjugated bilirubin at 3 mo 
< 7.5 μmol/L ( < 0.44 mg/dL) 18 1.00 (Ref) 1.00 (Ref) .407 
≥ 7.5 μmol/L ( ≥ 0.44 mg/dL) 14 20.4 (2.17–193) .008 6.38 (0.51–80.6) 
APRI at 3 mo † 
< 0.55 16 1.00 (Ref) 1.00 (Ref) .121 
≥ 0.55 15 23.3 (2.42–225) .006 9.96 (0.20–52.3) 
Total bilirubin at 6 mo 
< 7.5 μmol/L ( < 0.44 mg/dL) 17 1.00 (Ref) 
≥ 7.5 μmol/L ( ≥ 0.44 mg/dL) 15 9.29 (1.57–54.8) .014 
Conjugated bilirubin at 6 mo 
< 2.5 μmol/L ( < 0.15 mg/dL) 16 1.00 (Ref) 
≥ 2.5 μmol/L ( ≥ 0.15 mg/dL) 16 11.7 (1.94–70.2) .007 
APRI at 6 mo ‡ 
< 0.63 11 1.00 (Ref) 
≥ 0.63 18 8.75 (1.53–50.1) .015 
GT at 6 mo §
< 266 U/L 17 1.00 (Ref) 1.00 (Ref) .359 
≥ 266 U/L 13 13.5 (1.42–128) 0.023 5.21 (0.15–176) 
∗ Statistically signiﬁcant variables from simple regression were adjusted for in multiple regression. Liver func- 
tion tests with higher odds ratios (OR) in simple regression were chosen if signiﬁcant both 3 and 6months after 
portoenterostomy (PEostomy). ORs are reported with 95% conﬁdence intervals (CI). 
† Results missing for 1 patient. 
‡ Results missing for 3 patients. 
§ Results missing for 2 patients. APRI , aspartate aminotransferase to platelet ratio; GT , gamma glutamyl trans- 
ferase; PEostomy , portoenterostomy. 
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B  
lthe extent of ductular reaction is associated closely with both the
histologic stage of ﬁbrosis and liver expression of mesenchymal
markers and growth factors driving ﬁbrogenesis. 1 , 23–26 Indeed, the
minority of patients who demonstrate less progressive ﬁbrosis af-
ter successful PEostomy also express less pronounced ductular re-
action than others. 24,27 Retention of hydrophobic bile acids has
been shown to promote ductular reaction-driven ﬁbrosis in other
congenital cholangiopathies. 28 Accordingly, by reﬂecting eﬃcient
bile ﬂow and hepatic clearance of bile acids, very low postoper-
ative serum bilirubin levels may indicate less active ductular re-
action and, therefore, slower ﬁbrosis progression in BA. Although
understanding the mechanisms promoting ﬁbrosis in BA still war-
rants further research, bilirubin values within reference limits but
above the median were associated strongly with progressive liver
ﬁbrosis and cirrhosis, suggesting histologic liver injury may only be
reversed if very low bilirubin levels are achieved by PEostomy. 
When BA patients are not categorized according to the success
of PEostomy, a serum bilirubin cutoff of 34 μmol/L (2 mg/dL) at
3 months after PEostomy effectively segregates those with pro-
longed survival of with their native liver. 14,16 In contrast, early
prognosticators of survival of the native liver after COJ have been
incompletely characterized and appear to differ from those predict-
ing LT need among unselected BA patients. In line with our ﬁnd-
ings, greater levels of serum bilirubin, AST, APRI, and GT at 3 to 5
months after PEostomy have been suggested to be associated with
decreased survival of the native liver after COJ. 29,30 In our patients
who underwent protocol liver biopsies not warranted by their clin-
ical status, postoperative bilirubin outperformed other liver func-
tion tests in the prediction of survival of the native liver, follow-
up cirrhosis, and progression of ﬁbrosis; whereas other patient-
related and treatment-related factors had no association with thesePlease cite this article as: M. Hukkinen, A. Kerola and J. Lohi et al., Ve
native liver in patients with biliary atresia by deferring liver ﬁbrogenesutcomes. Very low serum bilirubin levels at 3 and 6 months af-
er PEostomy were associated with a 100% 5-year survival of the
ative liver, demonstrating that instead of the commonly used cut-
ffs of 34 or 20 μmol/L (1.2 or 1.7 mg/dL), only bilirubin levels ap-
roaching the lower limit of normal reﬂect an optimal postopera-
ive outcome. 
This study is limited by its relatively small sample size, the ret-
ospective design, and the possibility of sampling error inherent
o liver biopsies. Nevertheless, this work provides novel data on
he progression of histologic liver ﬁbrosis and its predictors among
atients who continue to live with their native liver and develop
hronic liver disease after a successful PEostomy. Of note, prospec-
ively collected follow-up biopsies were part of our postoperative
rotocol and were not inﬂuenced by the patient’s clinical status, al-
owing us to assess factors that predict progression of ﬁbrosis after
uccessful PEostomy. Although biopsies were obtained at variable
ges, follow-up age was unrelated to the progression of ﬁbrosis or
he presence of cirrhosis. 
In conclusion, among patients whose bilirubin normal-
zed after PEostomy, total and conjugated bilirubin < 12.5/7.5
mol/L (0.73/0.44 mg/dL) at 3 months after PEostomy and 
 7.5/2.5 μmol/L (0.44/0.15 mg/dL) at 6 months after PEostomy
redicted stable, nonprogressive ﬁbrosis, absence of cirrhosis, and
mproved survival of the native liver. Postoperative APRI and GT
evels were less consistently related to follow-up histopathology
nd showed no associations with survival of the native liver. Our
esults suggest an optimal postPEostomy outcome involves a rapid
ecrease of bilirubin close to the lower limit of normal. Further
esearch is needed to individualize the follow-up of patients with
A according to their postoperative risk for progression of their
iver disease. ry low bilirubin after portoenterostomy improves survival of the 
is, Surgery, https://doi.org/10.1016/j.surg.2018.10.032 
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Fig. 1. Cumulative native liver (NL) survival according to total and conjugated bilirubin levels three and six months after portoenterostomy (PE) among patients who cleared 
their jaundice. P values from the log-rank test are reported. A bilirubin cutoff of 12.5 μmol/L corresponds to 0.73 mg/dL, 7.5 μmol/L to 0.44 mg/dL, and 2.5 μmol/L to 0.15 
mg/dL, respectively. 
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Supplementary material associated with this article can be
ound, in the online version, at doi: 10.1016/j.surg.2018.10.032 . 
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